alexa Ultrasonographic Appearance of the Uterine Endometrium
ISSN: 2167-0420

Journal of Womens Health Care
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Ultrasonographic Appearance of the Uterine Endometrium in Sudanese Breast Cancer Women on Tamoxifen Therapy

Moawia E. Hummeida1, Randa Salah2, Ismail Hussien3, Gamal K. Adam4 and AbdelAziem A Ali5*

1Faculty of Medicine, Alneelain University, Sudan

2Faculty of Medicine, Khartoum University, Sudan

3Khartoum Teaching Hospital, Sudan

4Faculty of Medicine, Gadarif University, Sudan

5Faculty of Medicine, Kassala University, Sudan

*Corresponding Author:
AbdelAziem A Ali
Department of Obstetrics and Gynecology
Faculty of Medicine, Kassala University
Kassala, P.O. Box 496, Sudan
Tel: +249912351175
Fax: +249411823501
E-mail: [email protected]

Received date: November 29, 2014; Accepted date: December 30, 2014; Published date: January 03, 2015

Citation: Hummeida ME, Salah R, Hussien I, Adam GK, Ali AAA (2015) Ultrasonographic Appearance of the Uterine Endometrium in Sudanese Breast Cancer Women on Tamoxifen Therapy. J Women’s Health Care 4:215. doi:10.4172/2167-0420.1000215

Copyright: © 2015 Hummeida ME, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Although the potential benefit of Tamoxifen treatment in breast cancer patients outweighs its risk; however, all patients receiving Tamoxifen should undergo regular gynecologic evaluations. To survey the endometrial abnormality (endometrial thicknesses of 8 mm and more) using Trans-vaginal Ultrasound (TVS), data was collected prospectively from 104 patients with histologically confirmed stage I or II breast carcinoma, on Tamoxifen therapy for at least 6 months duration at Radiation and Isotopes Centre in Khartoum (RICK), Sudan during the period of June 2013 through December 2013. Means and proportions were compared between those with normal and abnormal endometrial thickness using student and chi-square test, respectively. P < 0.05 was considered significant. The mean (SD) duration of Tamoxifen use was 22 months. Among the total patients 39 (37.5%), 29 (27.8%), 20 (19.3%) and 16 (15.4%) used Tamoxifen for < 24, 24-36, 36-48 and ≥ 48 months respectively. Normal TVS was observed in 45 patients and abnormal findings were reported in 59 patients. In this study abnormal endometrial thickness was noticed more among nulliparous (p ≤ 0.001), longer duration of Tamoxifen use (p ≤ 0.001), premenopausal status (p ≤ 0.001), smoking (p ≤ 0.024) and BMI (p ≤ 0.001). In
Conclusion: Although the discussions about endometrial screening in patients receiving Tamoxifen are still controversial, our study revealed strong association between Tamoxifen therapy and endometrial abnormality.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version